Clinical trial / 2020
Nicotinamide (vitamin B3) supplementation improved inner retinal function in participants treated for glaucoma.
In a double-masked crossover trial, 57 glaucoma patients received oral placebo or nicotinamide (1.5 g/day for 6 weeks, then 3.0 g/day for 6 weeks) followed by crossover without washout. Saturated PhNR amplitude (Vmax) improved by 14.8% (95% CI: 2.8%, 26.9%; P = .02) on nicotinamide versus 5.2% (95% CI: -4.2%, 14.6%; P = .27) on placebo. The Vmax ratio improved by 12.6% (95% CI: 5.0%, 20.2%; P = .002) following nicotinamide compared to 3.6% (95% CI: -3.4%, 10.5%; P = .30) on placebo. Additionally, 27% of participants improved visual field mean deviation by ≥1 dB on nicotinamide with fewer deteriorating (4%) compared to placebo (P = .02).
- Study type
- Crossover, double-masked, randomized clinical trial
- Who was studied
- 57 participants diagnosed and treated for glaucoma
- What was measured
- Change in inner retinal function determined by photopic negative response (PhNR) parameters and visual field mean deviation
THE PAPER
Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: A crossover randomized clinical trial.
Hui F, Tang J, Williams PA, McGuinness MB, Hadoux X, Casson RJ, Coote M, Trounce IA, Martin KR, van Wijngaarden P, Crowston JG. Clin Exp Ophthalmol, 2020.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.